Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-center, Phase 2 Clinical Study of an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T Cell Therapy (C-CAR168) for the Treatment of Lupus Nephritis Refractory to Standard Therapy

NCT07729826 is registered in ClinicalTrials.gov with AbelZeta Inc. as lead sponsor.

NCT NCT07729826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07729826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-center, Phase 2 Clinical Study of an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T Cell Therapy (C-CAR168) for the Treatment of Lupus Nephritis Refractory to Standard Therapy
Lead sponsor
AbelZeta Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
September 1, 2029
Enrollment
50 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune diseases, lupus nephritis (ln), systemic lupus erythematosus (sle)